Optoderma takes on global psoriasis
This article was originally published in The Rose Sheet
Executive Summary
Company's products for the treatment of psoriasis will be available in the U.S., Canada and Mexico at the end of the month, it announces Nov. 21. Distribution in the U.S. will follow FDA registration as an over-the-counter drug. Optoderma also will expand to 21 countries in the Middle East around the same time through a distribution agreement with a United Arab Emirates company, firm adds. "Highly effective" Optoderma - which comes in cream, lotion and gel form for various applications - is currently sold throughout Europe, as well as online. In Germany, the product's turnover quintupled between January and September of this year, firm adds...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.